134 related articles for article (PubMed ID: 1310986)
1. Domain structure and interactions of recombinant urokinase-type plasminogen activator.
Novokhatny V; Medved L; Mazar A; Marcotte P; Henkin J; Ingham K
J Biol Chem; 1992 Feb; 267(6):3878-85. PubMed ID: 1310986
[TBL] [Abstract][Full Text] [Related]
2. Domain structure and domain-domain interactions of recombinant tissue plasminogen activator.
Novokhatny VV; Ingham KC; Medved LV
J Biol Chem; 1991 Jul; 266(20):12994-3002. PubMed ID: 1906462
[TBL] [Abstract][Full Text] [Related]
3. Tissue-type plasminogen activator (tPA) interacts with urokinase-type plasminogen activator (uPA) via tPA's lysine binding site. An explanation of the poor fibrin affinity of recombinant tPA/uPA chimeric molecules.
Novokhatny V; Medved L; Lijnen HR; Ingham K
J Biol Chem; 1995 Apr; 270(15):8680-5. PubMed ID: 7721771
[TBL] [Abstract][Full Text] [Related]
4. Domain structure and domain-domain interactions in human coagulation factor IX.
Vysotchin A; Medved LV; Ingham KC
J Biol Chem; 1993 Apr; 268(12):8436-46. PubMed ID: 8473287
[TBL] [Abstract][Full Text] [Related]
5. Unfolding studies of the protease domain of urokinase-type plasminogen activator: the existence of partly folded states and stable subdomains.
Nowak UK; Cooper A; Saunders D; Smith RA; Dobson CM
Biochemistry; 1994 Mar; 33(10):2951-60. PubMed ID: 8130209
[TBL] [Abstract][Full Text] [Related]
6. Effect of tethered peptidylchloromethylketone inhibitors on thermal stability and domain interactions of urokinase and other serine proteases.
Novokhatny VV; Medved LV; Mazar A; Ingham KC
J Biol Chem; 1993 Aug; 268(23):17211-8. PubMed ID: 8349606
[TBL] [Abstract][Full Text] [Related]
7. Domain structure and interactions of the type I and type II modules in the gelatin-binding region of fibronectin. All six modules are independently folded.
Litvinovich SV; Strickland DK; Medved LV; Ingham KC
J Mol Biol; 1991 Feb; 217(3):563-75. PubMed ID: 1994038
[TBL] [Abstract][Full Text] [Related]
8. The construction and expression of chimeric urokinase-type plasminogen activator genes containing kringle domains of human plasminogen.
Boutaud A; Castellino FJ
Arch Biochem Biophys; 1993 Jun; 303(2):222-30. PubMed ID: 8512311
[TBL] [Abstract][Full Text] [Related]
9. Tissue-type plasminogen activator domain-deletion mutant BM 06.022: modular stability, inhibitor binding, and activation cleavage.
Hu CK; Kohnert U; Wilhelm O; Fischer S; Llinás M
Biochemistry; 1994 Oct; 33(39):11760-6. PubMed ID: 7918392
[TBL] [Abstract][Full Text] [Related]
10. Domain-domain interactions in hybrids of tissue-type plasminogen activator and urokinase-type plasminogen activator.
Bakker AH; Nieuwenbroek NM; Verheijen JH
Protein Eng; 1995 Dec; 8(12):1295-1302. PubMed ID: 8869642
[TBL] [Abstract][Full Text] [Related]
11. The chemotactic action of urokinase on smooth muscle cells is dependent on its kringle domain. Characterization of interactions and contribution to chemotaxis.
Mukhina S; Stepanova V; Traktouev D; Poliakov A; Beabealashvilly R; Gursky Y; Minashkin M; Shevelev A; Tkachuk V
J Biol Chem; 2000 Jun; 275(22):16450-8. PubMed ID: 10749881
[TBL] [Abstract][Full Text] [Related]
12. A urokinase-type plasminogen activator-inhibiting cyclic peptide with an unusual P2 residue and an extended protease binding surface demonstrates new modalities for enzyme inhibition.
Hansen M; Wind T; Blouse GE; Christensen A; Petersen HH; Kjelgaard S; Mathiasen L; Holtet TL; Andreasen PA
J Biol Chem; 2005 Nov; 280(46):38424-37. PubMed ID: 16141208
[TBL] [Abstract][Full Text] [Related]
13. Reversible independent unfolding of the domains of urokinase monitored by 1H NMR.
Bogusky MJ; Dobson CM; Smith RA
Biochemistry; 1989 Aug; 28(16):6728-35. PubMed ID: 2790026
[TBL] [Abstract][Full Text] [Related]
14. Amino-terminal fragment of urokinase-type plasminogen activator inhibits its plasminogen activation.
Sun Z; Zhang PX; Wang P; Gurewich V; Shen HY; Liu JN
Thromb Res; 2002 Apr; 106(2):105-11. PubMed ID: 12182908
[TBL] [Abstract][Full Text] [Related]
15. Biological and clinical relevance of the urokinase-type plasminogen activator (uPA) in breast cancer.
Schmitt M; Goretzki L; Jänicke F; Calvete J; Eulitz M; Kobayashi H; Chucholowski N; Graeff H
Biomed Biochim Acta; 1991; 50(4-6):731-41. PubMed ID: 1801751
[TBL] [Abstract][Full Text] [Related]
16. Anti-angiogenic activity of the recombinant kringle domain of urokinase and its specific entry into endothelial cells.
Kim KS; Hong YK; Joe YA; Lee Y; Shin JY; Park HE; Lee IH; Lee SY; Kang DK; Chang SI; Chung SI
J Biol Chem; 2003 Mar; 278(13):11449-56. PubMed ID: 12529357
[TBL] [Abstract][Full Text] [Related]
17. Activation of the zymogen to urokinase-type plasminogen activator is associated with increased interdomain flexibility.
Behrens MA; Botkjaer KA; Goswami S; Oliveira CL; Jensen JK; Schar CR; Declerck PJ; Peterson CB; Andreasen PA; Pedersen JS
J Mol Biol; 2011 Aug; 411(2):417-29. PubMed ID: 21669207
[TBL] [Abstract][Full Text] [Related]
18. A hybrid protein of urokinase growth-factor domain and plasminogen-activator inhibitor type 2 inhibits urokinase activity and binds to the urokinase receptor.
Ballance DJ; Marshall JM; Cottingham IR; Steven J; Berry SJ; Cederholm-Williams SA; Goodey AR; Courtney M
Eur J Biochem; 1992 Jul; 207(1):177-83. PubMed ID: 1321039
[TBL] [Abstract][Full Text] [Related]
19. Tissue-type plasminogen activator mutants imitating urokinase in the peptide link between kringle and protease domains and at selected sites within the protease domain.
Hinzmann B; Wernicke D; Pfeifer M; Zacharias U; Fischer B; Eisenmenger F; Will H
Eur J Biochem; 1993 Apr; 213(1):437-43. PubMed ID: 8386628
[TBL] [Abstract][Full Text] [Related]
20. Analysis of a two-domain binding site for the urokinase-type plasminogen activator-plasminogen activator inhibitor-1 complex in low-density-lipoprotein-receptor-related protein.
Andersen OM; Petersen HH; Jacobsen C; Moestrup SK; Etzerodt M; Andreasen PA; Thøgersen HC
Biochem J; 2001 Jul; 357(Pt 1):289-96. PubMed ID: 11415462
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
